At LinkBIO we are committed to advancing the future of medicine through innovative approaches and cutting-edge technologies. Our pipeline leverages a variety of advanced platforms, including aptamer-based therapies, targeted protein degradation (TPD), and the exploration of novel drug mechanisms.

We are currently engaged in the discovery of new therapeutic targets for diseases such as Hemophilia A, Acute Venous Thromboembolism (VTE), and other serious conditions, using groundbreaking techniques like bivalent aptamers and proximity-induced activation. Our approach includes non-clinical studies to assess safety and efficacy, followed by clinical trials to evaluate the potential of our treatments in humans.